First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

Summary Objective . The clinical outcomes of poor performance status (PS) patients with epidermal growth factor receptor ( EGFR )-mutated non-small cell lung cancer (NSCLC) who are treated with osimertinib as a first-line treatment have not been sufficiently evaluated. This study aimed to assess the...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 2022-04, Vol.40 (2), p.430-437
Main Authors: Igawa, Satoshi, Fukui, Tomoya, Kasajima, Masashi, Ono, Taihei, Ozawa, Takahiro, Kakegawa, Mikiko, Kusuhara, Seiichiro, Sato, Takashi, Nakahara, Yoshiro, Hisashi, Mitsufuji, Sasaki, Jiichiro, Naoki, Katsuhiko
Format: Article
Language:English
Subjects:
Acrylamides
Aged
Aniline Compounds - adverse effects
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Chemotherapy
Diarrhea
Epidermal growth factor
Epidermal growth factor receptors
ErbB Receptors - genetics
Female
Gene deletion
Growth factors
Health services
Humans
Lung cancer
Lung diseases
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Male
Medicine
Medicine & Public Health
Mutation
Non-small cell lung carcinoma
Observational studies
Oncology
Patients
Pharmacology/Toxicology
Protein Kinase Inhibitors - adverse effects
Short Report
Small cell lung carcinoma
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Objective . The clinical outcomes of poor performance status (PS) patients with epidermal growth factor receptor ( EGFR )-mutated non-small cell lung cancer (NSCLC) who are treated with osimertinib as a first-line treatment have not been sufficiently evaluated. This study aimed to assess the efficacy and safety of osimertinib in chemotherapy-naive and poor PS (2 or more) patients with NSCLC harboring sensitive EGFR mutations. Materials and Methods. We assessed the clinical effects of osimertinib as a first-line treatment for patients with poor PS NSCLC with an exon 19 deletion or exon 21 L858R mutation in EGFR . All patients were administered osimertinib (80 mg/day) as the initial treatment. Results. Sixteen patients (nine women and seven men) who were treated between August 2018 and July 2021 were included in this study; their median age was 78 years. The overall objective response rate was 56.3%. The median progression-free survival (PFS) of the entire patient population was 10.5 months and the PS score improved in 8 of 16 patients (50%). The most common adverse event was acneiform rash (42%), followed by diarrhea (36%) and paronychia (36%); none of these were of grade ≥ 3. Interstitial lung disease occurred in 2 patients (12.5%); however, no treatment-related deaths occurred. Conclusion. Considering the findings of this study, osimertinib appears to be an effective and safe treatment option for patients with poor PS and advanced NSCLC harboring sensitive EGFR mutations. To obtain conclusive results, further studies with larger cohorts are warranted.
ISSN:0167-6997
1573-0646
DOI:10.1007/s10637-021-01195-2